Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial-Reference-Cited by-同舟云学术

Bevacizumab plus FOLFIRI after failure of platinum–etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial

Published:2023-03 Issue:3 Volume:24 Page:297-306
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Walter Thomas,Lievre Astrid,Coriat Romain,Malka David,Elhajbi Farid,Di Fiore Fréderic,Hentic Olivia,Smith Denis,Hautefeuille Vincent,Roquin Guillaume,Perrier Marine,Dahan Laetitia,Granger Victoire,Sobhani Iradj,Mineur Laurent,Niccoli Patricia,Assenat Eric,Scoazec Jean-Yves,Le Malicot Karine,Lepage Côme,Lombard-Bohas Catherine

Publisher

Elsevier BV

Subject

Oncology

Reference29 articles.

1. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol,2017

2. Extrapulmonary poorly differentiated NECs, including molecular and immune aspects;McNamara;Endocr Relat Cancer,2020

3. Gastroenteropancreatic high-grade neuroendocrine carcinoma;Sorbye;Cancer,2014

4. Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study;Hadoux;Endocr Relat Cancer,2022

5. Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis;McNamara;Ther Adv Med Oncol,2020

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRRT in high‐grade digestive neuroendocrine neoplasms (NET G3 and NEC);Journal of Neuroendocrinology;2024-09-07

2. A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas;European Journal of Cancer;2024-09

3. Systemtherapie von neuroendokrinen Neoplasien;DMW - Deutsche Medizinische Wochenschrift;2024-07-16

4. Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms;Journal of the National Comprehensive Cancer Network;2024-07

5. Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives;Cancers;2024-05-27